A Clinical Study of Long-Term Administration of Inpegsomatropin Injection in Participants With Idiopathic Short Stature Who Have Completed Phase Ⅲ Clinical Trials

Inclusion Criteria: * Participants previously enrolled in the ISS Phase III clinical study (Study Number: PEGPESEN-4-2-001) with good treatment compliance (80%-120%), for whom the investigator assesses that the benefit of continuing growth hormone therapy outweighs the risk, and who enter this extension study within 4 weeks after completion of the Phase III study. * Legal guardians understand and provide signed informed consent. Participants aged ≥ 8 years shall also provide signed informed consent. For participants under 8 years of age who are capable of expressing assent, their assent shall be explicitly documented. Exclusion Criteria: * Participants have received other growth-promoting therapies other than those specified in the protocol within 2 months prior to entry into this extension study, including but not limited to growth hormone, insulin-like growth factor-1 (IGF-1), etc. * Evidence of closed epiphyseal growth plates or achievement of near-adult height (defined as calculated HV \< 2 cm/year over at least 6 months, or bone age ≥ 16 years for males, bone age ≥ 14 years for females). * Other conditions under which, in the investigator's opinion, continuation in this extension study is inappropriate.